Literature DB >> 36201158

From In Vitro to Perioperative Vascular Tissue Engineering: Shortening Production Time by Traceable Textile-Reinforcement.

Saurav Ranjan Mohapatra1, Elena Rama2, Christoph Melcher3, Tobias Call1, Miriam Aischa Al Enezy-Ulbrich4, Andrij Pich4, Christian Apel1, Fabian Kiessling2, Stefan Jockenhoevel5.   

Abstract

BACKGROUND: The production of tissue-engineered vascular graft (TEVG) usually involves a prolonged bioreactor cultivation period of up to several weeks to achieve maturation of extracellular matrix and sufficient mechanical strength. Therefore, we aimed to substantially shorten this conditioning time by combining a TEVG textile scaffold with a recently developed copolymer reinforced fibrin gel as a cell carrier. We further implemented our grafts with magnetic resonance imaging (MRI) contrast agents to allow the in-vitro monitoring of the TEVG's remodeling process.
METHODS: Biodegradable polylactic-co-glycolic acid (PLGA) was electrospun onto a non-degradable polyvinylidene fluoride scaffold and molded along with copolymer-reinforced fibrin hydrogel and human arterial cells. Mechanical tests on the TEVGs were performed both instantly after molding and 4 days of bioreactor conditioning. The non-invasive in vitro monitoring of the PLGA degradation and the novel imaging of fluorinated thermoplastic polyurethane (19F-TPU) were performed using 7T MRI.
RESULTS: After 4 days of close loop bioreactor conditioning, 617 ± 85 mmHg of burst pressure was achieved, and advanced maturation of extracellular matrix (ECM) was observed by immunohistology, especially in regards to collagen and smooth muscle actin. The suture retention strength (2.24 ± 0.3 N) and axial tensile strength (2.45 ± 0.58 MPa) of the TEVGs achieved higher values than the native arteries used as control. The contrast agents labeling of the TEVGs allowed the monitorability of the PLGA degradation and enabled the visibility of the non-degradable textile component.
CONCLUSION: Here, we present a concept for a novel textile-reinforced TEVG, which is successfully produced in 4 days of bioreactor conditioning, characterized by increased ECM maturation and sufficient mechanical strength. Additionally, the combination of our approach with non-invasive imaging provides further insights into TEVG's clinical application.
© 2022. The Author(s).

Entities:  

Keywords:  Electrospun scaffolds; Non-invasive monitoring; Tissue-engineered vascular grafts

Year:  2022        PMID: 36201158     DOI: 10.1007/s13770-022-00482-0

Source DB:  PubMed          Journal:  Tissue Eng Regen Med        ISSN: 1738-2696            Impact factor:   4.451


  49 in total

1.  Functional arteries grown in vitro.

Authors:  L E Niklason; J Gao; W M Abbott; K K Hirschi; S Houser; R Marini; R Langer
Journal:  Science       Date:  1999-04-16       Impact factor: 47.728

Review 2.  Development of tissue engineered vascular grafts.

Authors:  G R Campbell; J H Campbell
Journal:  Curr Pharm Biotechnol       Date:  2007-02       Impact factor: 2.837

Review 3.  Achieving the ideal properties for vascular bypass grafts using a tissue engineered approach: a review.

Authors:  Sandip Sarkar; Thomas Schmitz-Rixen; George Hamilton; Alexander M Seifalian
Journal:  Med Biol Eng Comput       Date:  2007-03-06       Impact factor: 2.602

Review 4.  A decade of progress in tissue engineering.

Authors:  Ali Khademhosseini; Robert Langer
Journal:  Nat Protoc       Date:  2016-09-01       Impact factor: 13.491

5.  Ta ion implanted nanoridge-platform for enhanced vascular responses.

Authors:  Tae-Sik Jang; Jae Hwan Lee; Sungwon Kim; Cheonil Park; Juha Song; Hwan Jun Jae; Hyoun-Ee Kim; Jin Wook Chung; Hyun-Do Jung
Journal:  Biomaterials       Date:  2019-09-05       Impact factor: 12.479

6.  Development of decellularized human umbilical arteries as small-diameter vascular grafts.

Authors:  Liqiong Gui; Akihito Muto; Stephen A Chan; Christopher K Breuer; Laura E Niklason
Journal:  Tissue Eng Part A       Date:  2009-09       Impact factor: 3.845

7.  Primary graft infections.

Authors:  W H Edwards; R S Martin; J M Jenkins; W H Edwards; J L Mulherin
Journal:  J Vasc Surg       Date:  1987-09       Impact factor: 4.268

8.  Management of thoracic aortic graft infections with the omental flap.

Authors:  Samir Shah; Sammy Sinno; Darl Vandevender; Jeffery Schwartz
Journal:  Ann Plast Surg       Date:  2013-06       Impact factor: 1.539

Review 9.  Biofabrication of tissue engineering vascular systems.

Authors:  Qiao Zhang; Èlia Bosch-Rué; Román A Pérez; George A Truskey
Journal:  APL Bioeng       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.